More MS news articles for Aug 2001

Frequency and significance of anti-Ro (SS-A) antibodies in multiple sclerosis patients.

http://www.ncbi.nlm.nih.gov/cgi-bin/Entrez/referer?/htbin-post/Entrez/query_old%3fdb=m&form=6&uid=11493223&Dopt=r

Acta Neurol Scand 2001 Aug;104(2):83-7

de Andres C, Guillem A, Rodriguez-Mahou M, Lopez Longo FJ
Departments of Neurology, Immunology and Rheumatology, Hospital General Universitario Gregorio Maranon, Madrid, Spain.

OBJECTIVE:

To determine the frequency and significance of antinuclear (ANA), anticardiolipin (ACA) and anti-Ro (SS-A) antibodies in multiple sclerosis (MS) patients.

METHODS:

ANA (indirect immunofluorescence), ACA and anti-Ro (SS-A) antibodies (ELISA) were tested in sera of 42 patients with Poser defined MS and 50 healthy individuals.

RESULTS:

High levels of anti-Ro (SS-A) antibodies were found in 3 patients (7%) (vs 0 in the control group). Two of them had normal salivary gland biopsy. Clinical MS form was chronic-progressive in 2 cases and relapsing-remitting in the third one. Ten patients (23%) had low levels of ANA (vs 4%), none of them positive for anti-Ro (SS-A) antibodies. Only 1 patient (2%) with RR clinical form had ACA (vs 0). No clinical or neuroradiological differences with conventional MS patients were observed.

CONCLUSIONS:

ANA, ACA and anti-Ro (SS-A) antibodies in MS patients indicate an underlying autoimmune disease but our series suggests that they are an epiphenomenon of a more diffuse immunological dysfunction.

PMID: 11493223, UI: 21384452